Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • reema
    Member
    • Feb 2014
    • 27

    #1

    De-novo assembly PASA annotation

    Hello Everyone,

    We have recently generated two de-novo transcriptomics assembly for two different but related species. These new transcripts seem quite good on the basis of quality measurements, completeness and alignment with the previously sequenced genome and annotation. We were able to pick up novel genes and previously unannotated transcripts. In order to pick the alternate spliced transcripts we are currently trying running PASA (Program to Assemble Spliced Alignment) annotation.

    After PASA annotation, when I made a comparison between trinity transcripts, already existing annotation and PASA annotation in IGB. I find out a case where trinity transcripts fully supported by previously curated annotation as well as the RNASeq data, but no PASA annotation. PASA annotation only shows one fragment, rest of the parts not even present in the valid and failed .gff3 file generated by PASA [Figure]. This leads to few questions - for which I don’t have any answer. Here are my questions:
    1. Why there is this difference in the PASA annotation- when there is already manual curation and RNAseq depth evidences are present? And which one is correct?
    2. PASA annotation using blat and gmap for the alignment of transcripts to the genome. And we have also used blat to align the transcript to the genome. Then why there is different in two blat alignment?


    Data used for Transcriptomics assembly = 100 bp Paired end reads, non-strand specific

    Attached figure description:-

    Dark Blue colour = New assembled transcript annotation [this is the annotation generated by aligning assembled transcripts with the genome using blat].
    Orange = existing curated annotation.
    Red = PASA annotation
    Blue colours = shows valid alignment annotation for blat and gmap respectively.
    Read Depth = Green for control and Dark red = Knock-out

    Figure http://www.compbio.dundee.ac.uk/user/rsingh/Figure.jpeg

    I am very much looking forward for the reply. Any suggestions/view would be very helpful.

    Many Thanks,
    Reema,
  • reema
    Member
    • Feb 2014
    • 27

    #2
    Problem solved. For solution please see https://www.biostars.org/p/133348/

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
      by SEQadmin2



      CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

      Despite this, “CRISPR helped turn genome editing from a specialized technique into
      ...
      07-31-2026, 11:01 AM
    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM
    • SEQadmin2
      Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by SEQadmin2



      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
      ...
      07-09-2026, 11:10 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, 07-31-2026, 02:55 AM
    0 responses
    17 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-24-2026, 12:17 PM
    0 responses
    15 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-23-2026, 11:41 AM
    0 responses
    13 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-20-2026, 11:10 AM
    0 responses
    25 views
    0 reactions
    Last Post SEQadmin2  
    Working...